Switch to:
Also traded in: Germany

GuruFocus Financial Strength Rank measures how strong a company’s financial situation is. It is based on these factors

1. The debt burden that the company has as measured by its Interest coverage (current year).
2. Debt to revenue ratio. The lower, the better
3. Altman Z-score.

A company ranks high with financial strength is likely to withstand any business slowdowns and recessions.

Financial Strength : 5/10

vs
industry
vs
history
Cash to Debt 3.88
LXRX's Cash to Debt is ranked lower than
65% of the 962 Companies
in the Global Biotechnology industry.

( Industry Median: 59.90 vs. LXRX: 3.88 )
Ranked among companies with meaningful Cash to Debt only.
LXRX' s Cash to Debt Range Over the Past 10 Years
Min: 1.31  Med: 4.89 Max: No Debt
Current: 3.88
Equity to Asset 0.36
LXRX's Equity to Asset is ranked lower than
81% of the 715 Companies
in the Global Biotechnology industry.

( Industry Median: 0.67 vs. LXRX: 0.36 )
Ranked among companies with meaningful Equity to Asset only.
LXRX' s Equity to Asset Range Over the Past 10 Years
Min: 0.33  Med: 0.64 Max: 0.96
Current: 0.36
0.33
0.96
F-Score: 5
Z-Score: 0.46
M-Score: 2.96
GuruFocus Profitability Rank ranks how profitable a company is and how likely the company’s business will stay that way. It is based on these factors:

1. Operating Margin
2. Trend of the Operating Margin (5-year average). The company with an uptrend profit margin has a higher rank.
••3. Consistency of the profitability
4. Piotroski F-Score
5. Predictability Rank•

The maximum rank is 10. A rank of 7 or higher means a higher profitability and may stay that way. A rank of 3 or lower indicates that the company has had trouble to make a profit.

Profitability Rank is not directly related to the Financial Strength Rank. But if a company is consistently profitable, its financial strength will be stronger.

Profitability & Growth : 5/10

vs
industry
vs
history
Operating margin (%) -9.31
LXRX's Operating margin (%) is ranked higher than
66% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -88.13 vs. LXRX: -9.31 )
Ranked among companies with meaningful Operating margin (%) only.
LXRX' s Operating margin (%) Range Over the Past 10 Years
Min: -9955.46  Med: -639.94 Max: 1.13
Current: -9.31
-9955.46
1.13
Net-margin (%) -11.87
LXRX's Net-margin (%) is ranked higher than
66% of the 743 Companies
in the Global Biotechnology industry.

( Industry Median: -75.28 vs. LXRX: -11.87 )
Ranked among companies with meaningful Net-margin (%) only.
LXRX' s Net-margin (%) Range Over the Past 10 Years
Min: -10120.39  Med: -606.25 Max: -3.6
Current: -11.87
-10120.39
-3.6
ROE (%) -9.77
LXRX's ROE (%) is ranked higher than
68% of the 874 Companies
in the Global Biotechnology industry.

( Industry Median: -34.32 vs. LXRX: -9.77 )
Ranked among companies with meaningful ROE (%) only.
LXRX' s ROE (%) Range Over the Past 10 Years
Min: -63.41  Med: -43.42 Max: -1.64
Current: -9.77
-63.41
-1.64
ROA (%) -4.07
LXRX's ROA (%) is ranked higher than
73% of the 972 Companies
in the Global Biotechnology industry.

( Industry Median: -30.23 vs. LXRX: -4.07 )
Ranked among companies with meaningful ROA (%) only.
LXRX' s ROA (%) Range Over the Past 10 Years
Min: -32.59  Med: -27.19 Max: -0.83
Current: -4.07
-32.59
-0.83
ROC (Joel Greenblatt) (%) -94.29
LXRX's ROC (Joel Greenblatt) (%) is ranked higher than
64% of the 925 Companies
in the Global Biotechnology industry.

( Industry Median: -407.53 vs. LXRX: -94.29 )
Ranked among companies with meaningful ROC (Joel Greenblatt) (%) only.
LXRX' s ROC (Joel Greenblatt) (%) Range Over the Past 10 Years
Min: -414.95  Med: -161.37 Max: 70.58
Current: -94.29
-414.95
70.58
Revenue Growth (3Y)(%) 328.10
LXRX's Revenue Growth (3Y)(%) is ranked higher than
99% of the 480 Companies
in the Global Biotechnology industry.

( Industry Median: 4.20 vs. LXRX: 328.10 )
Ranked among companies with meaningful Revenue Growth (3Y)(%) only.
LXRX' s Revenue Growth (3Y)(%) Range Over the Past 10 Years
Min: -71.6  Med: -3.4 Max: 328.1
Current: 328.1
-71.6
328.1
EPS Growth (3Y)(%) -68.60
LXRX's EPS Growth (3Y)(%) is ranked lower than
98% of the 507 Companies
in the Global Biotechnology industry.

( Industry Median: -3.10 vs. LXRX: -68.60 )
Ranked among companies with meaningful EPS Growth (3Y)(%) only.
LXRX' s EPS Growth (3Y)(%) Range Over the Past 10 Years
Min: -68.6  Med: -13.2 Max: 29.1
Current: -68.6
-68.6
29.1
GuruFocus has detected 2 Warning Signs with Lexicon Pharmaceuticals Inc $LXRX.
More than 500,000 people have already joined GuruFocus to track the stocks they follow and exchange investment ideas.
» LXRX's 10-Y Financials

Financials (Next Earnings Date: 2017-03-01)


Revenue & Net Income
Cash & Debt
Oprt. Cash Flow & Free Cash Flow
Oprt. Cash Flow & Net Income

» Details

Guru Trades

Q1 2016

LXRX Guru Trades in Q1 2016

Joel Greenblatt 189,317 sh (New)
Chuck Royce 340,589 sh (+31.20%)
Mario Gabelli 16,100 sh (unchged)
» More
Q2 2016

LXRX Guru Trades in Q2 2016

Paul Tudor Jones 12,351 sh (New)
Joel Greenblatt 295,094 sh (+55.87%)
Mario Gabelli 16,100 sh (unchged)
Chuck Royce Sold Out
» More
Q3 2016

LXRX Guru Trades in Q3 2016

Paul Tudor Jones 41,850 sh (+238.84%)
Mario Gabelli 14,600 sh (-9.32%)
Joel Greenblatt 47,635 sh (-83.86%)
» More
Q4 2016

LXRX Guru Trades in Q4 2016

Mario Gabelli 14,600 sh (unchged)
Paul Tudor Jones 30,574 sh (-26.94%)
Joel Greenblatt 27,102 sh (-43.10%)
» More
» Details

Insider Trades

Latest Guru Trades with LXRX

(List those with share number changes of more than 20%, or impact to portfolio more than 0.1%)

No Entry found in the selected group of Gurus. You can
  • 1. Modify your Personalized List of Gurus, or
  • 2. Click on Premium Premium Tools above to check out all the Gurus, or
  • 3. Click on Premium Plus Premium Plus above for the stocks picks of all the institutional investment advisors (>4000)
» Interactive Charts

Peter Lynch Chart ( What is Peter Lynch Charts )

Business Description

Industry: Biotechnology » Biotechnology    NAICS: 325414    SIC: 2836
Compare:NAS:AVXS, NAS:HALO, NAS:BGNE, NAS:AAAP, NAS:FGEN, NAS:SRPT, NAS:TBPH, NYSE:CBM, NAS:DBVT, NAS:PTLA, NAS:PBYI, NAS:FWP, OTCPK:MPSYY, NAS:FPRX, NAS:PRTA, NAS:ARRY, NAS:INVA, NAS:ONCE, NAS:NKTR, NYSE:EBS » details
Traded in other countries:LX31.Germany,
Lexicon Pharmaceuticals Inc operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease.

Lexicon Pharmaceuticals Inc was incorporated in Delaware on July 7, 1995. The Company operates as a biopharmaceutical company engaged in discovery and development of breakthrough treatments for human disease. It has used its proprietary gene knockout technology and an integrated platform of advanced medical technologies to systematically study the physiological and behavioral functions of almost 5,000 genes in mice and assessed the utility of the proteins encoded by the corresponding human genes as potential drug targets. It has identified and validated in living animals, or in vivo, more than 100 targets with promising profiles for drug discovery. The Company has also advanced small molecule compounds from a number of additional drug programs into various stages of preclinical development and research and believe that its systematic, target biology-driven approach to drug discovery will enable it to continue to expand its clinical pipeline. It faces significant competition in each of the aspects of its business from other pharmaceutical and biotechnology companies. The development, manufacture and sale of any drug or biologic products developed by the Company or its collaborators will be subject to extensive regulation by United States and foreign governmental authorities, including federal, state and local authorities.

Ratios

vs
industry
vs
history
Price/Owner Earnings (ttm) 12.28
LXRX's Price/Owner Earnings (ttm) is ranked higher than
76% of the 143 Companies
in the Global Biotechnology industry.

( Industry Median: 29.18 vs. LXRX: 12.28 )
Ranked among companies with meaningful Price/Owner Earnings (ttm) only.
LXRX' s Price/Owner Earnings (ttm) Range Over the Past 10 Years
Min: 5.41  Med: 11.73 Max: 27.88
Current: 12.28
5.41
27.88
P/B 8.58
LXRX's P/B is ranked lower than
82% of the 1106 Companies
in the Global Biotechnology industry.

( Industry Median: 3.65 vs. LXRX: 8.58 )
Ranked among companies with meaningful P/B only.
LXRX' s P/B Range Over the Past 10 Years
Min: 0.66  Med: 3.32 Max: 10.65
Current: 8.58
0.66
10.65
P/S 8.45
LXRX's P/S is ranked higher than
60% of the 853 Companies
in the Global Biotechnology industry.

( Industry Median: 12.50 vs. LXRX: 8.45 )
Ranked among companies with meaningful P/S only.
LXRX' s P/S Range Over the Past 10 Years
Min: 2.62  Med: 23.26 Max: 1440
Current: 8.45
2.62
1440
PFCF 11.40
LXRX's PFCF is ranked higher than
76% of the 140 Companies
in the Global Biotechnology industry.

( Industry Median: 22.44 vs. LXRX: 11.40 )
Ranked among companies with meaningful PFCF only.
LXRX' s PFCF Range Over the Past 10 Years
Min: 4.92  Med: 10.71 Max: 21.58
Current: 11.4
4.92
21.58
POCF 11.38
LXRX's POCF is ranked higher than
74% of the 204 Companies
in the Global Biotechnology industry.

( Industry Median: 21.56 vs. LXRX: 11.38 )
Ranked among companies with meaningful POCF only.
LXRX' s POCF Range Over the Past 10 Years
Min: 4.9  Med: 10.57 Max: 14.09
Current: 11.38
4.9
14.09
Current Ratio 2.34
LXRX's Current Ratio is ranked lower than
70% of the 950 Companies
in the Global Biotechnology industry.

( Industry Median: 4.13 vs. LXRX: 2.34 )
Ranked among companies with meaningful Current Ratio only.
LXRX' s Current Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.47 Max: 31.11
Current: 2.34
0.95
31.11
Quick Ratio 2.34
LXRX's Quick Ratio is ranked lower than
67% of the 948 Companies
in the Global Biotechnology industry.

( Industry Median: 3.91 vs. LXRX: 2.34 )
Ranked among companies with meaningful Quick Ratio only.
LXRX' s Quick Ratio Range Over the Past 10 Years
Min: 0.95  Med: 6.47 Max: 31.11
Current: 2.34
0.95
31.11
Days Sales Outstanding 1.44
LXRX's Days Sales Outstanding is ranked higher than
96% of the 592 Companies
in the Global Biotechnology industry.

( Industry Median: 62.87 vs. LXRX: 1.44 )
Ranked among companies with meaningful Days Sales Outstanding only.
LXRX' s Days Sales Outstanding Range Over the Past 10 Years
Min: 1.44  Med: 22.17 Max: 461.86
Current: 1.44
1.44
461.86

Buy Back

vs
industry
vs
history
3-Year Average Share Buyback Ratio -12.30
LXRX's 3-Year Average Share Buyback Ratio is ranked lower than
53% of the 556 Companies
in the Global Biotechnology industry.

( Industry Median: -10.90 vs. LXRX: -12.30 )
Ranked among companies with meaningful 3-Year Average Share Buyback Ratio only.
LXRX' s 3-Year Average Share Buyback Ratio Range Over the Past 10 Years
Min: -52  Med: -21.7 Max: -6.9
Current: -12.3
-52
-6.9

Valuation & Return

vs
industry
vs
history
Price/Net Cash 25.07
LXRX's Price/Net Cash is ranked lower than
86% of the 749 Companies
in the Global Biotechnology industry.

( Industry Median: 5.89 vs. LXRX: 25.07 )
Ranked among companies with meaningful Price/Net Cash only.
LXRX' s Price/Net Cash Range Over the Past 10 Years
Min: 1.17  Med: 7.1 Max: 92.26
Current: 25.07
1.17
92.26
Price/Net Current Asset Value 23.89
LXRX's Price/Net Current Asset Value is ranked lower than
89% of the 879 Companies
in the Global Biotechnology industry.

( Industry Median: 5.57 vs. LXRX: 23.89 )
Ranked among companies with meaningful Price/Net Current Asset Value only.
LXRX' s Price/Net Current Asset Value Range Over the Past 10 Years
Min: 1.13  Med: 6.44 Max: 302.75
Current: 23.89
1.13
302.75
Price/Tangible Book 18.20
LXRX's Price/Tangible Book is ranked lower than
91% of the 1015 Companies
in the Global Biotechnology industry.

( Industry Median: 4.36 vs. LXRX: 18.20 )
Ranked among companies with meaningful Price/Tangible Book only.
LXRX' s Price/Tangible Book Range Over the Past 10 Years
Min: 0.89  Med: 4.29 Max: 44.55
Current: 18.2
0.89
44.55
Price/Median PS Value 0.36
LXRX's Price/Median PS Value is ranked higher than
87% of the 765 Companies
in the Global Biotechnology industry.

( Industry Median: 0.97 vs. LXRX: 0.36 )
Ranked among companies with meaningful Price/Median PS Value only.
LXRX' s Price/Median PS Value Range Over the Past 10 Years
Min: 0.11  Med: 0.45 Max: 50.48
Current: 0.36
0.11
50.48
Earnings Yield (Greenblatt) (%) -1.26
LXRX's Earnings Yield (Greenblatt) (%) is ranked higher than
72% of the 1203 Companies
in the Global Biotechnology industry.

( Industry Median: -9.03 vs. LXRX: -1.26 )
Ranked among companies with meaningful Earnings Yield (Greenblatt) (%) only.
LXRX' s Earnings Yield (Greenblatt) (%) Range Over the Past 10 Years
Min: -1.27  Med: 19.45 Max: 1944.4
Current: -1.26
-1.27
1944.4

More Statistics

Revenue (TTM) (Mil) $187.6
EPS (TTM) $ -0.23
Beta0.01
Short Percentage of Float44.80%
52-Week Range $8.37 - 19.62
Shares Outstanding (Mil)104.04

Analyst Estimate

Dec16 Dec17 Dec18 Dec19
Revenue (Mil $) 78 74 82 228
EPS ($) -1.61 -1.65 -1.78 -0.04
EPS w/o NRI ($) -1.61 -1.65 -1.78 -0.04
EPS Growth Rate
(3Y to 5Y Estimate)
N/A
Dividends Per Share ($)
» More Articles for LXRX

Headlines

Articles On GuruFocus.com
Lexicon Genetics Inc. Reports Operating Results (10-Q) Nov 08 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 09 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) May 10 2010 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Oct 30 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Aug 06 2009 
Lexicon Genetics Inc. Reports Operating Results (10-Q) Apr 30 2009 

More From Other Websites
Lexicon To Present At The Leerink Partners 6th Annual Global Healthcare Conference Feb 13 2017
The Zacks Analyst Blog Highlights: Synergy Pharmaceuticals, Amgen, Valeant Pharmaceuticals... Feb 01 2017
4 FDA Decisions to Watch Out for in Feb 2017 Jan 31 2017
Lexicon Begins Phase 1 Clinical Trial Of Locally-acting SGLT1 Inhibitor, LX2761, For Potential... Jan 09 2017
Lexicon To Present At The 35th Annual J.P. Morgan Healthcare Conference Jan 05 2017
7 Key FDA Decisions and Catalysts Expected in January and February Dec 30 2016
Blog Coverage Lexicon Pharma's Tandem2 Phase 3 Clinical Trial of Sotagliflozin Met its Primary... Dec 22 2016
Lexicon Reports Positive Top-line Results In Second Pivotal Phase 3 Study For Sotagliflozin In... Dec 21 2016
Lexicon Pharmaceuticals, Inc. – Value Analysis (NASDAQ:LXRX) : December 19, 2016 Dec 19 2016
Lexicon Pharmaceuticals, Inc. breached its 50 day moving average in a Bullish Manner : LXRX-US :... Dec 16 2016
Biotech Movers And Shakers: Lexicon Pharmaceuticals, Inc. (LXRX) And Neuroderm Ltd (NDRM) Dec 06 2016
TherapeuticsMD Soars On Positive Menopause Drug Clinical Trial Results Dec 06 2016
Lexicon Reports Top-Line Results From Phase 2 Clinical Trial Conducted In Collaboration With JDRF Dec 05 2016
10 Major Pharma and FDA Catalysts Coming in December Dec 05 2016
Lexicon Pharmaceuticals, Inc. (LXRX): Are Hedge Funds Right About This Stock? Dec 02 2016
Lexicon Announces the Establishment of the Commercial Leadership Team for Telotristat Ethyl Nov 21 2016
Lexicon Announces The Establishment Of The Commercial Leadership Team For Telotristat Ethyl Nov 21 2016

Personalized Checklist

Checklist has been moved to "Checklist" tab.

Get WordPress Plugins for easy affiliate links on Stock Tickers and Guru Names | Earn affiliate commissions by embedding GuruFocus Charts
GuruFocus Affiliate Program: Earn up to $400 per referral. ( Learn More)